<p>Researchers in Prof. Samuel Strober’s laboratory have developed a new immunotherapy protocol for treating patients with solid tumors, including those with metastatic disease. This therapy begins with adjuvant-enhanced vaccination using the patient’s purified tumor cells, followed by autologous hematopoietic cell transplantation (HCT). The invention also describes novel methods for purifying the tumor cells. Compared to traditional immunotherapy, this treatment does not require ex vivo expansion of cells or cytokine treatment. Also, because the HCT uses cells from the patient, there is no risk of graft vs. host disease (GVHD). Although neither vaccination nor HCT are effective alone, combining the two created a synergistic effect that resulted in uniform cures in a mouse model of colon cancer. This technology could be particularly useful for patients at high risk for relapse.Stage of Research
The inventors demonstrated the efficacy of this treatment protocol in a mouse model of colon cancer.